Patient Education Webinar： Belzutifan

On May 14, 2025, the US Food and Drug Administration (FDA) approved belzutifan for adults and children over 12 years of age, who have pheochromocytoma (pheo) or paraganglioma (para) that has spread to nearby tissues, metastasized, not able to be removed surgically, or unable to be cured through other treatment options. The data from the clinical trial, that led to FDA approval, was presented at the ESMO Conference in mid-October by Dr. Camilo Jimenez. This education webinar, presented by Dr. Camilo Jimenez, is the first time that this data has been shared with the patient population. The information presented on this webinar is for educational purposes only and should not substitute the advice of your doctor(s) and medical team because they have in-depth knowledge of your medical history and current situation. Timings and questions are as follows: 58:10 -- Q1: Does tumor location factor into a treatment plan? And with that tumor location, if genetic versus non-genetic markers play into whether Belzutifan is a good treatment option? And VHL or non-VHL as well. 1:03:16 -- Q2: What are some considerations that there are in determining when in the treatment plan to take Belzutifan for metastatic pheo/para? Is there a good time to bring this up as well to maybe transition from something else that they might be taking? 1:07:34 -- Q3: Do you know any insight into whether Belzutifan is available internationally? 1:09:12 -- Q4: Is there something that was unique about the 15%...